Greykasell Wealth Strategies Inc. Makes New $504,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Greykasell Wealth Strategies Inc. acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, HoldingsChannel.com reports. The firm acquired 708 shares of the biopharmaceutical company’s stock, valued at approximately $504,000.

Several other large investors have also recently bought and sold shares of the company. State Street Corp lifted its holdings in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after buying an additional 61,277 shares in the last quarter. Amundi lifted its holdings in Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after buying an additional 487,489 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company’s stock valued at $495,639,000 after purchasing an additional 22,538 shares during the period. Swiss National Bank lifted its stake in shares of Regeneron Pharmaceuticals by 0.6% in the 3rd quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after purchasing an additional 2,000 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company’s stock valued at $215,562,000 after purchasing an additional 1,108 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on REGN. Sanford C. Bernstein cut their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Citigroup cut their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Wells Fargo & Company dropped their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Finally, Canaccord Genuity Group initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Stock Down 2.0 %

NASDAQ REGN opened at $666.87 on Friday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20. The company has a 50 day moving average of $694.91 and a 200-day moving average of $836.31. The company has a market cap of $72.91 billion, a price-to-earnings ratio of 17.42, a PEG ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the business earned $11.86 earnings per share. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.